When a new active substance (a molecule that has never been marketed in Canada in any form) receives its Notice of Compliance (i.e., marketing approval), relatively little is known about its safety profile. This situation exists for a number of reasons, including the relatively homogeneous nature of the population enrolled in premarket clinical trials, the use of pre-randomization run-in periods, the short-term nature of many trials, and the relatively small number of patients in these trials.[@ref1],[@ref2]

One measure of the limited initial information about safety is the number of new active substances---just under 1 in 4---for which Health Canada eventually issues a serious safety warning (a warning in bold black lettering and/or a boxed warning) or that must be withdrawn from the market because of safety concerns.[@ref3] Drugs in the latter category are the ones with the most serious safety issues, because whatever their therapeutic benefits, they are too dangerous to remain on the market. Looking at this group of drugs can provide insights into the strengths and weaknesses of both the pre- and the post-market safety evaluation systems.

Since the early 1990s, there have been a number of changes to the Canadian regulatory system that may have affected its ability to detect safety problems before drugs are approved and to monitor the safety of drugs once they are on the market. In 1994, Health Canada instituted a system of cost recovery from pharmaceutical companies to cover part of the operating costs of the drug regulatory system. Critics have charged that user fees have redirected the orientation of Health Canada away from drug safety toward faster processing of new drug applications and a higher approval rate.[@ref4] New drug approval times in Canada declined significantly after 2006,[@ref5] and shorter times for approving new drug applications have been linked to more postmarket safety problems.[@ref3],[@ref6] In 2002, Health Canada reorganized its postmarket safety system, creating the Marketed Health Products Directorate, and dedicated \$7 million in new funding in fiscal year 2002/2003 to strengthen post-market surveillance activities concerned with safety and effectiveness.[@ref7] Between 2004 and 2010, the ratio of funding and personnel allocated by Health Canada to the directorates that review new drug applications to the funding and personnel for the Marketed Health Products Directorate improved from about 7:1 to 3.5:1.[@ref8]

Specifically, this study considered 2 questions: Has there been a change in the percentage of new active substances approved in 5-year periods between the start of 1990 and the end of 2009 that are eventually withdrawn because of safety reasons? How long are new active substances on the market before their serious safety problems requiring withdrawal are recognized? In addition, 2 secondary questions were examined: For drugs that are eventually withdrawn that first receive a serious safety warning, what is the period between approval of the drug and its first serious safety warning, and what is the period between the safety warning and eventual withdrawal?

Methods {#S1}
=======

Identification and classification of drugs withdrawn from the Canadian market {#S1a}
-----------------------------------------------------------------------------

A list of all drugs withdrawn from the Canadian market between 1 January 1990 and 1 October 2013 and the reason for withdrawal was compiled from Lexchin[@ref9] and Health Canada\'s MedEffect website ([www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/index-eng.php)). Withdrawals of specific lots of a drug due to manufacturing problems were excluded. This list was narrowed to those approved from 1 January 1990 to 31 December 2009 using the Notice of Compliance website ([www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/notices-avis/index-eng.php)). For each of these drugs the following information was recorded: generic name, date of Notice of Compliance, and date of and reason for market withdrawal. Each drug was classified at the third level of the World Health Organization\'s Anatomical Therapeutic Chemical system.[@ref10]

The total number of new active substances approved in consecutive 5-year periods (1990--1994, 1995--1999, 2000--2004, 2005--2009) was obtained from the annual reports of the Therapeutic Products Directorate and the Biologic and Genetic Therapies Directorate (available by contacting the directorates directly at <publications@hc-sc.gc.ca>).

Identification of serious safety warnings before withdrawal {#S1b}
-----------------------------------------------------------

For each drug that was withdrawn, the MedEffect website was used to identify whether the product had received a serious safety warning before its withdrawal and, if so, the date of the warning. Serious safety advisories issued because of misuse of a drug (e.g., an unapproved use) or medication errors (e.g., neglecting to remove a transdermal patch before applying a second one) were excluded. When necessary, notices on the MedEffect web site were supplemented by searching the product name in the Drug Product Database (<http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp>). For example, a notice that one product, gatifloxacin, had been withdrawn from the market never appeared on the MedEffect website, and the withdrawal was confirmed only on the Drug Product Database website.

Discrepancies in data sources {#S1c}
-----------------------------

For 4 drugs, the data sources yielded conflicting information. Troglitazone was approved but never marketed in Canada because of a dispute about its introductory price. There was no information about revocation of its Notice of Compliance on the MedEffect website. The drug was removed from the US market in March 2000, and 15 March 2000 was arbitrarily used as its withdrawal date in Canada. It was retained in the analysis because it was approved and then later shown to have side effects serious enough that it was withdrawn. The announcement about the withdrawal of cisapride made reference to a safety warning in February 2000 but the exact date was not stated; the date of the safety warning was therefore arbitrarily set to 14 February. Amphetamine salts were withdrawn on 9 February 2005 but allowed back on the market on 24 August 2005 and were therefore not included in the list of drugs withdrawn for safety reasons. Nesiritide was withdrawn by the company marketing the product but no reason was given, so it was also excluded from analysis.

Statistical analysis {#S1d}
--------------------

The percentages of new active substances withdrawn in the four 5-year periods were compared using the χ^2^ test (AcaStat 8.2.3, AcaStat Software). The following time periods were calculated in days: from Notice of Compliance to first serious safety warning, from Notice of Compliance to withdrawal, and from first serious safety warning to withdrawal. These calculations were done with Excel 2011 for Macintosh (Microsoft Inc.)

Funding and ethics approval {#S1e}
---------------------------

There was no funding for this study, and no ethics approval was required because all of the information came from publicly available databases.

Results {#S2}
=======

A total of 528 new active substances were approved between 1 January 1990 and 31 December 2009; of these, 22 (4.2%, 95% confidence interval 2.5%--5.9%) were withdrawn ([Table 1](#T1){ref-type="table"}). Nineteen of the drugs were withdrawn for safety reasons and 2 (drotrecogin alfa and idebenone) were withdrawn because of a negative benefit-to-harm ratio rather than a specific safety problem. The reason for withdrawal of ceftobiprole was vaguely given as concerns regarding the conduct of clinical trials, and it is not clear that safety was an issue.

###### 

Drugs eventually withdrawn for safety reasons relative to all new active substances approved in various 5-year periods, from 1 January 1990 to 31 December 2009[\*](#T1FN2){ref-type="table-fn"}

  Variable                                                               Approval period; no. or % of products                                                      
  ---------------------------------------------------------------------- --------------------------------------- ---------------- ---------------- ---------------- ----------------
  No. of new active substances approved                                  129                                     166              119              114              528
  No. of products eventually withdrawn[†](#T1FN3){ref-type="table-fn"}   5                                       7                5                5                22
  \% of new active substances withdrawn (95% CI)                         3.9 (0.6--7.2)                          4.2 (1.2--7.3)   4.2 (0.6--7.8)   4.4 (0.6--8.2)   4.2 (2.5--5.9)

CI = confidence interval.

No difference among 5-year periods (χ^2^ = 0.04, *p* = 0.99).

Withdrawals anytime between 1 January 1990 and 1 October 2013.

Between 3.9% and 4.4% of the drugs approved in each 5-year period were eventually withdrawn (χ^2^ = 0.04, p = 0.99 for differences among periods) ([Table 1](#T1){ref-type="table"}).

Of the 22 drugs withdrawn, 11 first had a serious safety warning and 11 did not ([Table 2](#T2){ref-type="table"}). The median time between the Notice of Compliance and withdrawal was 1271 days (interquartile range 706--2876). For the 11 drugs with a prior safety warning, the median time between Notice of Compliance and the warning was 907 days (interquartile range 196--1525), and the median time between the warning and withdrawal was 329 days (interquartile range 119--893). Two of the drugs (sitaxsentan and valdecoxib) received a safety warning 20 days after their Notice of Compliance. Cerivastatin and lumiracoxib were withdrawn 23 and 48 days, respectively, after their respective safety warnings.

###### 

Drugs withdrawn for safety reasons[\*](#T2FN2){ref-type="table-fn"}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Generic name                       ATC classification\       Event; date (yr-mo-d)   Intervals, d   Reason for withdrawal                                                         
                                     (third level)                                                                                                                                  
  ---------------------------------- ------------------------- ----------------------- -------------- ----------------------- ------------------ ----------------- ---------------- ---------------------------------------------
  Pergolide                          Dopaminergic              1991-06-27              None issued    2007-08-30              5908               NA                NA               Valvulopathy

  Cisapride                          Propulsive                1991-08-15              2000-02-14     2000-08-07              3280               3105              175              Cardiovascular events

  Calcitonin\                        Antiparathyroid           1992-07-13              None issued    2013-10-01              7750               NA                NA               Malignancies
  (synthetic, salmon)                                                                                                                                                               

  Remoxipride                        Antipsychotic             1993-07-26              None issued    1994-03-14              231                NA                NA               Aplastic anemia

  Nefazodone                         Antidepressant            1994-04-27              2001-06-20     2003-11-27              3501               2611              890              Hepatotoxicity

  Dexfenfluramine                    Antiobesity               1996-07-09              1996-10-21     1997-09-15              433                104               329              Valvulopathy

  Troglitazone                       Glucose lowering          1997-05-09              None issued    2000-03-15              1041               NA                NA               Hepatotoxicity

  Tolcapone                          Dopaminergic              1997-10-08              None issued    1998-11-20              408                NA                NA               Hepatotoxicity

  Cerivastatin                       Lipid-modifying agent     1998-02-18              2001-07-16     2001-08-08              1267               1244              23               Rhabdomyolysis

  Grepafloxacin                      Quinolone antibacterial   1998-04-09              None issued    1999-10-26              565                NA                NA               Cardiovascular events

  Trovafloxacin                      Quinolone antibacterial   1998-12-04              None issued    2001-11-22              1084               NA                NA               Hepatotoxicity

  Rofecoxib                          Anti-inflammatory         1999-10-25              2002-04-19     2004-09-30              1802               907               895              Cardiovascular events

  Sibutramine                        Antiobesity               2000-12-28              2002-03-27     2010-10-08              3571               454               3117             Cardiovascular events

  Gatifloxacin                       Quinolone antibacterial   2001-01-09              2005-12-19     2006-06-29              1997               1805              192              Glucose metabolism disorders

  Tegaserod                          For constipation          2002-03-12              None issued    2007-03-30              1844               NA                NA               Cardiovascular events

  Valdecoxib                         Anti-inflammatory         2002-12-11              2002-12-31     2005-04-07              848                20                828              Skin reactions

  Drotrecogin alfa                   Antithrombotic            2003-02-20              None issued    2011-10-25              3169               NA                NA               Failure to show benefit

  Efalizumab                         Immunosuppressant         2005-10-24              2008-12-22     2009-02-22              1217               1155              62               Progressive multifocal leuko-encephalopathy

  Lumiracoxib                        Anti-inflammatory         2006-11-02              2007-08-16     2007-10-03              335                287               48               Hepatotoxicity

  Sitaxsentan                        Antihypertensive          2007-06-19              2007-07-09     2010-12-15              1275               20                1255             Hepatotoxicity

  Ceftobiprole                       β-Lactam antibacterial    2008-06-26              None issued    2010-04-16              659                NA                NA               Conduct of clinical trials

  Idebenone                          Psychostimulant           2008-07-23              None issued    2013-02-27              1680               NA                NA               Failure of efficacy studies

  **Median (interquartile range)**                                                                                            1271 (706--2876)   907 (196--1525)   329 (119--893)   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ATC = Anatomical Therapeutic Chemical classification system,10 NA = not applicable, NOC = Notice of Compliance.

Ordered by date of approval.

At the third level of the Anatomical Therapeutic Chemical classification system, 2 classes---quinolone antibacterials and anti-inflammatories---were responsible for 3 drugs each; in addition, 2 of the drugs withdrawn were dopaminergic agents and 2 were for the treatment of obesity. Drugs were withdrawn primarily because of cardiovascular events, including valvulopathy (7 products), or because of hepatotoxicity (6 products) ([Table 2](#T2){ref-type="table"}).

Interpretation {#S3}
==============

There was no difference in the percentage of drugs approved in the four 5-year periods that were eventually withdrawn from the market. The absence of any change indicates that the ability of the drug review system to detect serious safety issues and keep those drugs off the market did not change over the time period examined and similarly that there was no change in the rigour of the postmarket surveillance system. The discrepancy between the change in the number of reported adverse drug reactions (ADRs) and the change in the number of prescriptions filled suggests another explanation. From 1998 to 2011, the number of ADRs rose from 4663[@ref11] to 41 923,[@ref12] an increase of 799%, whereas the number of retail prescriptions rose only 107%, from 254 187 000[@ref13] to 524 952 000.[@ref14] If the postmarket surveillance system became better able to identify ADRs while the percentage of products withdrawn remained the same, then one possibility is that, over time, the premarket review system was becoming less stringent. Distinguishing between these competing explanations would require access to internal Health Canada documents to explore the reasons behind decisions about drug approvals and safety withdrawals.

The overall 4.2% figure for withdrawals in this study is generally in line with US and European values, although it is higher than the 2.9% (16 of 548 new molecular entities, the US equivalent of a new active substance) reported by Lasser et al.[@ref15] for the United States between 1975 to 1999 and lower than the 5.5% (16 out of 289) of new active substances approved by the European Medicines Agency between 1 January 1999 and 31 December 2009.[@ref16] The median time to withdrawal for the 16 drugs in the study by Lasser et al.[@ref15] was about 620 days, which is just under half the median of 1271 days in the study reported here. (Times in days from the study by Lasser et al.[@ref15] are approximations, since those authors reported times in years and fractions of years.) Five of the 16 drugs withdrawn in the United States, as reported by Lasser et al.,[@ref15] had a prior safety warning, with a median time between approval and the safety warning of 1241 days (interquartile range 1095--1460) and a median time between the safety warning and withdrawal of 1168 days (interquartile range 730--1497). The duration for the same intervals in Canada was 907 and 327 days, respectively. There are a number of possible explanations for these differences, including the mix of drugs approved in the different time periods, differences in the relative strengths and weakness of the US and Canadian drug regulatory systems, and differences in the willingness of the regulatory authorities to take action. Lasser et al.[@ref15] also reported that cardiovascular events (4 products) and hepatotoxicity (3 products) were the major reasons for withdrawals.

Just as important as the percentage of withdrawals is whether there has been a change in how many people are exposed to drugs before they are withdrawn. As an example, in 2003, the year before rofecoxib was removed from the market, it was the 10th most frequently prescribed medication in Canada.[@ref17] Unfortunately, there are no publicly available data to answer this question.

The 1271-day median time between Notice of Compliance and withdrawal emphasizes the need to be particularly cautious in prescribing new drugs early in their life cycle. Conversely, a prolonged period on the market is no guarantee of safety. It took over 21 years (7750 days) to recognize problems with synthetic salmon calcitonin. The short intervals between marketing approval and a serious safety warning and between a safety warning and withdrawal raise questions about both the pre- and the post-market safety evaluations: Was Health Canada unaware of the safety problems with sitaxsentan and valdecoxib when it approved these drugs? What changed in the few weeks between when a safety warning was issued about cerivastatin and lumiracoxib and when they were withdrawn? Eleven of the 22 drugs that were withdrawn had no prior safety warning. Was Health Canada unaware of any safety issues associated with these products before they were withdrawn? Health Canada documents describing what triggers a safety action are vague and give little indication about how decisions are made. For example, Health Canada states \"The determination of the seriousness of risk (probability of health hazard and probability of occurrence) and urgency of risk communication is based on sound scientific judgement.\"[@ref18]

This study had several limitations. The withdrawal of one drug (ceftobiprole) may have been for reasons other than safety. The definition of a serious safety warning was based on the way that Health Canada displayed the information (bold black print and/or boxed text), but the criteria that Health Canada used in deciding on its safety warnings and the emphasis that it placed on any particular safety issue are unknown. There were inconsistencies in the Health Canada databases. Some drugs identified as \"new active substances\" in the annual reports of the Therapeutic Products Directorate were not called \"new active substances\" in the Notice of Compliance online query website. The date on which a new active substance receives a Notice of Compliance is not necessarily the date on which the company decides to market the drug; therefore, the length of time the drug was available before it received a safety warning and/or was withdrawn may have been shorter than what is reported here. However, no information about when a drug is first sold is publicly available. Finally, follow-up for individual drugs ranged from slightly more than 3 years to over 23 years. Further safety withdrawals may occur, especially with more recently approved products. The effect on the results presented here would depend on the number of future withdrawals and when the particular products were approved.

This research emphasizes that a small but not insignificant number of drugs that are approved will eventually be found to be too unsafe to remain on the market. It also raises questions about the thoroughness of Health Canada\'s pre- and post-market evaluations of drug safety.
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